ET-19 A PHASE 1 STUDY EVALUATING ABT-414 WITH TEMOZOLOMIDE (TMZ) OR CONCURRENT RADIOTHERAPY (RT) AND TMZ IN GLIOBLASTOMA (GBM)

BACKGROUND: Standard therapies have little effect on the poor survival rates of GBM. Abnormal epidermal growth factor receptor (EGFR) expression and signaling are common in GBM. ABT-414 is a unique antibody-drug conjugate, with a toxic payload (MMAF) targeted to active EGFR or mutant EGFRvIII, that...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gan, Hui K., Fichtel, Lisa, Lassman, Andrew B., Merrell, Ryan, van den Bent, Martin, Kumthekar, Priya, Scott, Andrew M., Pedersen, Michelle, Gomez, Erica, Fischer, JuDee, Ames, William, Xiong, Hao, Dudley, Matt, Munasinghe, Wijith, Roberts-Rapp, Lisa, Ansell, Peter, Holen, Kyle, Reardon, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218114/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou255.19
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados